Gyre Therapeutics, Inc.
$7.94
▼
-1.52%
2026-04-21 07:14:00
www.gyretx.com
NCM: GYRE
Explore Gyre Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$725.03 M
Current Price
$7.94
52W High / Low
$11.78 / $6.57
Stock P/E
144.23
Book Value
$1.16
Dividend Yield
—
ROCE
7.77%
ROE
8.21%
Face Value
—
EPS
$0.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
625
Beta
6.4
Debt / Equity
0.66
Current Ratio
5.6
Quick Ratio
5.04
Forward P/E
123.17
Price / Sales
6.11
Enterprise Value
$659.58 M
EV / EBITDA
47.08
EV / Revenue
5.66
Rating
None
Target Price
$18.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 2. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 3. | GRI Bio, Inc. | $2.51 | — | $3.68 M | — | -198.85% | -2.38% | $80.36 / $2.1 | $12.07 |
| 4. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
| 5. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 6. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 7. | Protara Therapeutics, Inc. | $5.3 | — | $286.65 M | — | -32.51% | -31.6% | $7.82 / $2.77 | $3.67 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 37.2 M | 30.56 M | 26.77 M | 22.06 M | 27.87 M | — |
| Operating Profit | 0.12 M | 6.93 M | 2.17 M | 2.27 M | 0.66 M | — |
| Net Profit | -1.72 M | 3.61 M | 0.44 M | 2.7 M | -0.1 M | — |
| EPS in Rs | -0.02 | 0.04 | 0 | 0.03 | -0 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 116.59 M | 105.76 M | 113.45 M | 102.29 M |
| Operating Profit | 11.49 M | 16.23 M | 19.21 M | 9.2 M |
| Net Profit | 5.03 M | 12.09 M | -92.93 M | 2.3 M |
| EPS in Rs | 0.06 | 0.13 | -1.02 | 0.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 166.13 M | 125.41 M | 116.54 M | 84.75 M |
| Total Liabilities | 23.85 M | 27 M | 102.59 M | 12.54 M |
| Equity | 106.03 M | 63.32 M | -15.83 M | 42.52 M |
| Current Assets | 102.37 M | 64.79 M | 57.22 M | 49.65 M |
| Current Liabilities | 18.29 M | 19.52 M | 20.05 M | 12.24 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.01 M | -3.64 M | 25.89 M | 10.68 M |
| Investing CF | -0.47 M | -19.88 M | -19.76 M | -13.81 M |
| Financing CF | 24.38 M | 2.1 M | 2.5 M | 0 M |
| Free CF | -0.91 M | -6.77 M | 17.31 M | 5.68 M |
| Capex | -1.92 M | -3.13 M | -8.59 M | -5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.78% | 10.91% | — | — |
| Earnings Growth % | 113% | -4137.05% | — | — |
| Profit Margin % | 11.43% | -81.92% | 2.25% | — |
| Operating Margin % | 15.35% | 16.94% | 9% | — |
| Gross Margin % | 96.33% | 95.91% | 95.31% | — |
| EBITDA Margin % | 16.85% | 17.92% | 10.1% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2023-01-13 | $3.6 |
| 2022-09-21 | $21.45 |
Stock Splits
| Date | Split |
|---|---|
| 2023-10-31 | 1:0.0666667 |